Health
Super-backed company develops COVID treatment – Financial Standard
A biotech company backed by AustralianSuper, HESTA, Hostplus and Statewide Super has developed a new preventative treatment shown to reduce COVID-19 levels by u…
A biotech company backed by AustralianSuper, HESTA, Hostplus and Statewide Super has developed a new preventative treatment shown to reduce COVID-19 levels by up to 96%.
The product, INNA-051, is being developed by Ena Respiratory, and works by stimulating and boosting the innate immune system. The study found that boosting the immune system this way limits the ability of the COVID-19 virus to infect the animals used in the study.
Ena Respiratory raised $11.7 million from a coalition of instit…
-
General20 hours agoAccused of Antisemitism: Herald Sun, Israel lobby v Dandenong Clr Rhonda Garad
-
Noosa News23 hours agoRaising your voice | Noosa Today
-
Noosa News20 hours agoMitch Power Quick Shear event gets men talking about mental health
-
General10 hours agoWallaroos fall to Black Ferns 37-12 in Wellington Test